Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Prior treatment

• Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
• Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing
  • Phase 2a
• Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
• Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing
• Receipt of immunosuppressant therapies or biologic therapy for asthma within 6 months of screening
• Other investigational agent(s) within 30 days of dosing

Other illness

• Evidence of clinically significant condition or disease
• Any physical or psychological condition that prohibits study completion
• History of severe allergic reactions or hypersensitivity
• Evidence of clinically significant condition or disease
• History of severe allergic reactions or hypersensitivity
• Current or former smoker with a smoking history of ≥10 pack-years

• Age 18-65
• Must be in good health with no significant medical history
• Willing and able to attend all study visits, comply with study requirements
• Able and willing to provide written informed consent
• Age 18-65
• Must be in good health with no significant medical history
• Willing and able to attend all study visits, comply with study requirements.
• Able and willing to provide written informed consent
• Documented asthma diagnosis prior for at least 12 months prior to screening.
• Symptomatic asthma
• Currently receiving maintenance asthma medications

Criteria the registry did not label

• Phase 1